{"title":"Global patent landscape in breast cancer metastasis","authors":"Martin Perez-Santos, M. Anaya-Ruiz","doi":"10.33582/2638-4248/1006","DOIUrl":"https://doi.org/10.33582/2638-4248/1006","url":null,"abstract":"Cite this article: Perez-Santos M, Anaya-Ruiz M. Global patent landscape in breast cancer metástasis. Chronicles Oncol. 2018; 2: 1006. Martín Perez-Santos1,2*; Maricruz Anaya-Ruiz3 1Oficina de Comercialización de Tecnología, Centro Universitario de Vinculación y transferecnia de Tecnología, Benemérita Universidad Autónoma de Puebla, México 2Pharma Patent Consultancy, México 3Laboratorio de Biología Celular, Centro de Investigación Biomédica de Oriente, México","PeriodicalId":433633,"journal":{"name":"Chronicles of Oncology","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134505982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"How to overcome endocrine resistance in early and metastatic breast cancer","authors":"E. Biskup, M. Vetter","doi":"10.33582/2638-4248/1005","DOIUrl":"https://doi.org/10.33582/2638-4248/1005","url":null,"abstract":"According to St. Gallen Consensus, endocrine responsive breast cancer is defined by positive steroidal receptors (ER= estrogen receptor and PR= Progesterone Receptor). ER/PR and HER2 are the most important biomarkers in decisionmaking about adjuvant and palliative treatment options. Available data suggest, that the higher the expression of ER and PR, the better the outcome for patients with early and advanced breast cancers.","PeriodicalId":433633,"journal":{"name":"Chronicles of Oncology","volume":"76 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124675389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Matthew Kelling, Kansas City Missouri Usa Biosciences, M. Dimza, S. Dalia, Joplin Missouri Usa Biosciences
{"title":"Risk of myocarditis in patients with cancer treated with immune checkpoint inhibitors","authors":"Matthew Kelling, Kansas City Missouri Usa Biosciences, M. Dimza, S. Dalia, Joplin Missouri Usa Biosciences","doi":"10.33582/2638-4248/1004","DOIUrl":"https://doi.org/10.33582/2638-4248/1004","url":null,"abstract":"Cite this article: Kelling M, Dimza M, Dalia S. Risk of myocarditis in patients with cancer treated with immune checkpoint inhibitors. Chronicles Oncol. 2018; 1: 1004. Matthew Kelling MS1; Michelle Dimza1; Samir Dalia MD2* 1Kansas City University of Medicine and Biosciences, Kansas City, Missouri, USA 2Adjunct Clinical Assistant Professor of Hematology/Oncology, Kansas City University of Medicine and Biosciences, Joplin, Missouri, USA","PeriodicalId":433633,"journal":{"name":"Chronicles of Oncology","volume":"52 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123647375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
